562091-56-9

Basic information

• Product Name: IMidafenacin IMpurity (1-(3-Cyano-3,3-Diphenylpropyl)-2-Methyl-1H-IMidazoliuM Phosphate)
• Synonyms: IMidafenacin IMpurity (1-(3-Cyano-3,3-Diphenylpropyl)-2-Methyl-1H-IMidazoliuM Phosphate);Imidafenacin Impurity 7
• CAS NO: 562091-56-9
• Molecular Formula: C₂₀H₁₉N₃*H₃O₄P
• Molecular Weight: 399.380141
• Mol File: 562091-56-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: IMidafenacin IMpurity (1-(3-Cyano-3,3-Diphenylpropyl)-2-Methyl-1H-IMidazoliuM Phosphate)(CAS DataBase Reference)
• NIST Chemistry Reference: IMidafenacin IMpurity (1-(3-Cyano-3,3-Diphenylpropyl)-2-Methyl-1H-IMidazoliuM Phosphate)(562091-56-9)
• EPA Substance Registry System: IMidafenacin IMpurity (1-(3-Cyano-3,3-Diphenylpropyl)-2-Methyl-1H-IMidazoliuM Phosphate)(562091-56-9)

Safety Data

• Hazardous Substances Data: 562091-56-9(Hazardous Substances Data)

Upstream product

• 214777-43-2 4-(2-methyl-1H-imidazol-1-yl)-2,2-diphenylbutanenitrile 
• 39186-58-8 4-bromo-2,2-diphenylbutyronitrile 

Downstream Products

• 170105-16-5 imidafenacin 

Relevant articles and documents

2,4-(1H, 3H)-quinazolinedione derivative and synthesis method and use thereof

The present invention discloses a 2,4-(1H,3H)-quinazolinedione derivative and a synthesis method and use thereof, belongs to the technical field of medicines, and relates to the 2,4-(1H, 3H)-quinazolinedione derivative shown as general formula(I), wherein R1 is O(CH2)n-1H, n=1-10; or NH(CH2)n-2H, n=2-10; or NH(CH2)n-3(CH3)2, n=3-10; or N(CH2)n-4, n=6-10; or NH(CH2)n-5 C6H4-L, n=5-10; R2 is H; or X-O(CH2)n-1H, n=1-10; or X-NH(CH2)n-2(CH3)2, n=2-10; X is m-CH2C6H4CO; L is independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, CF3, OCF3, SCF3, OH, SH, NH2, COOR, R, OR, SR, NHR, NRR, OCOR, SCOR and NHCOR, wherein R is C1-6 straight chain alkyl, branched alkyl or alicyclic alkyl or phenyl. Structures and the synthesis method and in-vitro acetylcholin esterase inhibition activity of the compounds are disclosed, and the compounds can be further developed as drugs for treating Alzheimer's disease.

PROCESS FOR PRODUCING MUSCARINE RECEPTOR ANTAGONIST AND INTERMEDIATE THEREFOR

The industrial production of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutanamide, a urinary incontinence remedy, necessitates elimination of problems concerning the use of a synthetic adsorbent, e.g., HP-20, the efficiency of operation with the same, purification efficiency, etc. An acid salt, e.g., hydrochloride or phosphate, of 4-(2-methyl-1-imidazolyl)-2,2- diphenylbutanamide or a hydrate of any of these salts is used as an intermediate. This intermediate is neutralized and then purified. Thus, high-purity 4-(2-methyl -1-imidazolyl)-2,2-diphenylbutanamide is easily obtained in satisfactory yield. The industrial-scale production process has been thus established.